Latest Information Update: 19 Jun 2001
At a glance
- Originator Nippon Kayaku; Toyama Medical and Pharmaceutical University
- Class Antineoplastics
- Mechanism of Action Type II DNA topoisomerase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 19 Jun 2001 Discontinued-Preclinical for Cancer in Japan (Unknown route)
- 19 Mar 1993 Preclinical development for Cancer in Japan (Unknown route)